{"Abstract": [0], "It": [1], "has": [2, 33, 134], "been": [3, 142, 165], "more": [4], "than": [5], "three": [6], "decades": [7], "since": [8], "the": [9, 16, 56, 67, 74, 78, 86, 118, 128, 168, 181, 187, 194, 208], "first": [10], "monoclonal": [11, 97, 204], "antibody": [12, 31, 37, 98, 132, 189, 198, 210, 215], "was": [13, 100], "approved": [14, 143, 166], "by": [15, 117, 125, 167], "United": [17], "States": [18], "Food": [19], "and": [20, 27, 81, 108, 122, 154, 185, 217, 223], "Drug": [21], "Administration": [22], "(US": [23], "FDA)": [24], "in": [25, 63, 77, 82, 106, 193], "1986,": [26], "during": [28], "this": [29], "time,": [30], "engineering": [32, 190], "dramatically": [34], "evolved.": [35], "Current": [36], "drugs": [38, 61, 76, 90, 133, 140], "have": [39, 54, 72, 141, 164], "increasingly": [40], "fewer": [41], "adverse": [42], "effects": [43], "due": [44], "to": [45, 111], "their": [46], "high": [47], "specificity.": [48], "As": [49, 157], "a": [50], "result,": [51], "therapeutic": [52, 96, 131, 162, 197], "antibodies": [53, 71], "become": [55, 73], "predominant": [57], "class": [58], "of": [59, 85, 114, 120, 158, 196, 203], "new": [60, 139], "developed": [62], "recent": [64], "years.": [65], "Over": [66], "past": [68], "five": [69], "years,": [70], "best-selling": [75], "pharmaceutical": [79], "market,": [80], "2018,": [83], "eight": [84], "top": [87], "ten": [88], "bestselling": [89], "worldwide": [91], "were": [92], "biologics.": [93], "The": [94], "global": [95], "market": [99, 129, 183], "valued": [101], "at": [102], "approximately": [103], "US$115.2": [104], "billion": [105, 116, 124], "2018": [107], "is": [109, 173], "expected": [110], "generate": [112], "revenue": [113], "$150": [115], "end": [119], "2019": [121], "$300": [123], "2025.": [126], "Thus,": [127], "for": [130, 144], "experienced": [135], "explosive": [136], "growth": [137, 176], "as": [138, 201], "treating": [145], "various": [146], "human": [147, 209], "diseases,": [148], "including": [149], "many": [150], "cancers,": [151], "autoimmune,": [152], "metabolic": [153], "infectious": [155], "diseases.": [156], "December": [159], "2019,": [160], "79": [161], "mAbs": [163], "US": [169], "FDA,": [170], "but": [171], "there": [172], "still": [174], "significant": [175], "potential.": [177], "This": [178], "review": [179], "summarizes": [180], "latest": [182], "trends": [184], "outlines": [186], "preeminent": [188], "technologies": [191], "used": [192], "development": [195], "drugs,": [199], "such": [200], "humanization": [202], "antibodies,": [205], "phage": [206], "display,": [207], "mouse,": [211], "single": [212], "B": [213], "cell": [214], "technology,": [216], "affinity": [218], "maturation.": [219], "Finally,": [220], "future": [221], "applications": [222], "perspectives": [224], "are": [225], "also": [226], "discussed.": [227]}